s-1743 and Hypertension--Portal

Liver cirrhosis is associated with increased intrahepatic resistance due to hepatic fibrosis and exaggerated vasoconstriction. Recent studies have indicated that proton pump inhibitors (PPIs), in addition to acid suppression, modulate vasoactive substances and vasoresponsiveness. PPIs are frequently prescribed in patients with cirrhosis due to a higher prevalence of peptic ulcers, however other impacts are unknown.. Esomeprazole did not affect hepatic ET-1 vasoresponsiveness. The hepatic protein expressions of the aforementioned factors were not significantly different among the groups. There were no significant differences in hemodynamics, liver biochemistry and hepatic fibrosis after chronic esomeprazole administration.. PPIs did not affect hepatic vasoresponsiveness or the release of vasoactive substances. Furthermore, they did not influence hemodynamics, liver biochemistry or severity of hepatic fibrosis in the cirrhotic rats.

Topics: Animals; Endothelin-1; Esomeprazole; Hemodynamics; Hypertension, Portal; Liver Cirrhosis, Experimental; Male; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley

Topics: Aged; Anti-Ulcer Agents; Body Mass Index; Duodenal Ulcer; Duodenitis; Esomeprazole; Humans; Hypertension, Portal; Ischemia; Liver Cirrhosis, Alcoholic; Male; Risk Factors; Stomach Ulcer; Treatment Outcome